Poster Downloads_Biocytogen Pharmaceuticals (Beijing) Co., Ltd._Biocytogen, drug development, antibody discovery

top

Please input keywords

EN

Management team

Social Responsibility

Antibody Assets

Project Integrum

Antibody discovery platforms

Clinical pipeline

Preclinical pipeline

Humanized animal models

KO mouse models

Immunodeficient mice/rats

Disease mouse models

Pharmacology Service

Therapeutic area

Types of services

By technologies

Animal Breeding

Animal Cryopreservation

Animal Rederivation

Microbial detection

Animal Breeding

Animal Cryopreservation

Animal Rederivation

Stock Information

Financial Reports

Listing Documents

Announcements & Notices

Corporate Governance

Investor Calendar

Poster Downloads

Media Center

Poster Downloads

Brochure

AACR 2024: A first-in-class bispecific ADC targeting FOLR1 and MUC1 exhibits promising anti-tumor activity in a FOLR1low xenograft model

AACR 2024: BCG033, a novel bispecific antibody-drug conjugate targeting PTK7 and TROP2, demonstrates preclinical efficacy against triple-negative breast cancer and other solid tumor xenografts

AACR 2024: TIL analysis demonstrates different mechanisms underlying PD-1 resistance in animal models

AACR 2024: Generation of a novel severely immunodeficient Sprague Dawley rat model for xenograft studies

AACR 2024: A novel humanized NKP46 mouse model to support xenograft studies evaluating NK cell-based cancer immunotherapies

AACR 2024: A novel humanized CD16A model to evaluate efficacy of human antibody therapeutics in triggering ADCC

AACR 2024: Development and validation of humanized HLA mouse model platforms for preclinical evaluation of novel peptide vaccines

AACR 2024: Establishment of a humanized IL5/IL5RA mouse model to evaluate modulators of eosinophilic inflammation in vivo

AACR 2024: Development of humanized VEGFA models to assess preclinical efficacy of novel therapeutics in vivo

1 2 3 4 5 … 15